Samsung Bioepis inks first major deal with Intracell for ADC cancer drug development

Samsung Bioepis has entered into a significant collaboration with Intracell, signing its first main contract to jointly develop an antibody-drug conjugate (ADC) cancer therapy. This agreement signifies a crucial step in advancing their partnership, which began with joint research into potential cancer treatments. The core of the contract involves the further development and commercialization of a specific candidate substance, designated 'SBE303'. This collaboration aims to accelerate the journey of promising ADC candidates from the research phase to potential market availability. The companies initially identified this candidate during their joint research efforts, and this new contract solidifies their commitment to bringing it to fruition. The move underscores Samsung Bioepis's strategic focus on expanding its oncology pipeline through innovative therapeutic approaches like ADCs.